

February 2, 2017 - Frequently Asked Questions and Answers – (FAQs)

From time to time, Merck Investor Relations will provide FAQs on various topics of interest. The following are recent FAQs.

Key words: Trius Therapeutics Contingent Value Right

Will payment be made under the Trius Contingent Value Rights?

In January 2015, Merck & Co., Inc. (“Merck”) acquired Cubist Pharmaceuticals, Inc. (“Cubist”) which, in 2013, had acquired Trius Therapeutics (“Trius”). The contingent value rights (“CVRs”) received by Trius shareholders as part of the 2013 Trius/Cubist transaction remained an obligation of Cubist, now a wholly-owned Merck subsidiary. Payments were to be made under those CVRs only if SIVEXTRO (tedizolid phosphate) achieved \$125 million in net sales in 2016 in specified territories. Net sales for SIVEXTRO in 2016 were \$14 million; therefore payment will not be made under the Trius CVRs.

DISCLOSURE NOTICE:

This FAQ contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this presentation should be evaluated together with the many uncertainties that affect Merck's business, particularly those mentioned in the risk factors and cautionary statements in Item 1A of Merck's Form 10-K for the year ended Dec. 31, 2015.

Investor Contacts:
Amy Klug – 908-740-1898
Mike DeCarbo – 908-740-1807